- Home
- UTG vs CNTA Comparison
UTG vs CNTA Comparison
Compare UTG & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UTG | CNTA |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.5B |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UTG | CNTA |
|---|---|---|
| Price | $42.13 | $26.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $39.50 |
| AVG Volume (30 Days) | 278.2K | ★ 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.75 | $9.60 |
| 52 Week High | $41.99 | $30.58 |
Technical Indicators
Market Signals| Indicator | UTG | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 76.03 | 62.40 |
| Support Level | $36.11 | $21.93 |
| Resistance Level | N/A | $30.29 |
| Average True Range (ATR) | 0.65 | 1.11 |
| MACD | 0.19 | 0.26 |
| Stochastic Oscillator | 97.26 | 80.04 |
Price Performance
Historical ComparisonAbout UTG Reaves Utility Income Fund of Beneficial Interest
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.